AMGLIDIA (Glibenclamide)
Oral suspension for the treatment of neonatal diabetes mellitus
Quick Facts About AMGLIDIA
Key Takeaways About AMGLIDIA
- First licensed pediatric formulation: AMGLIDIA is the only commercially available oral suspension of glibenclamide, designed specifically for neonates and infants who cannot swallow tablets
- Replaces insulin in many cases: In neonatal diabetes caused by KCNJ11 or ABCC8 mutations, AMGLIDIA can effectively replace daily insulin injections with oral medication
- Precise dose titration: Available in two strengths (0.6 mg/mL and 6 mg/mL) with graduated syringes, allowing accurate dosing from birth
- Neurodevelopmental benefits: Early treatment with glibenclamide in KCNJ11 neonatal diabetes has been shown to improve neurodevelopmental outcomes beyond glycemic control alone
- Monitor for hypoglycemia: The main safety concern is low blood sugar, which requires careful glucose monitoring especially during dose titration
What Is AMGLIDIA and What Is It Used For?
AMGLIDIA is an oral suspension containing glibenclamide (also known as glyburide) that is specifically developed for treating neonatal diabetes mellitus (NDM) in newborns, infants, and children. It is the first and only commercially available liquid formulation of a sulfonylurea, approved by the European Medicines Agency (EMA) in 2018 with orphan drug designation.
Neonatal diabetes mellitus is an extremely rare form of diabetes, typically diagnosed within the first six months of life. Unlike the more common type 1 diabetes, which is caused by autoimmune destruction of pancreatic beta cells, neonatal diabetes is caused by genetic mutations that affect how the pancreas produces or releases insulin. This condition can be life-threatening if untreated, causing severe hyperglycemia and diabetic ketoacidosis.
The most common cause of permanent neonatal diabetes mellitus (PNDM) is mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium (KATP) channel in pancreatic beta cells. These mutations account for approximately 30-50% of all PNDM cases. Mutations in the ABCC8 gene, encoding the SUR1 subunit of the same channel, are another significant cause. In both cases, the KATP channels remain permanently open, preventing the normal cascade of insulin release in response to glucose.
Glibenclamide, the active ingredient in AMGLIDIA, works by directly binding to the SUR1 subunit and closing the dysfunctional KATP channels. This mechanism effectively bypasses the genetic defect, restoring glucose-dependent insulin secretion. In patients with responsive mutations, this means that insulin injections can often be replaced entirely by oral glibenclamide therapy, dramatically improving quality of life for both patients and their families.
Before AMGLIDIA, healthcare providers had to crush glibenclamide tablets and prepare extemporaneous liquid formulations, which led to inconsistent dosing and variable bioavailability. AMGLIDIA addresses this critical gap by providing a standardized, validated oral suspension with consistent drug concentration, supplied with graduated oral syringes for precise measurement. This is particularly important in neonates, where even small variations in dose can have significant clinical consequences.
AMGLIDIA received orphan drug designation from the EMA in January 2016 due to the extreme rarity of neonatal diabetes mellitus, which affects approximately 1 in 90,000 to 1 in 160,000 live births worldwide. This designation provides regulatory incentives to support the development of treatments for rare conditions.
What Should You Know Before Taking AMGLIDIA?
Before starting AMGLIDIA, genetic testing should confirm a KATP channel mutation responsive to sulfonylureas. Contraindications include diabetic ketoacidosis, type 1 diabetes, severe liver or kidney impairment, and concurrent use of bosentan. Special caution is needed in newborns under 4 weeks due to the sodium benzoate content.
AMGLIDIA should only be prescribed following a thorough clinical evaluation and, ideally, after genetic confirmation of a sulfonylurea-responsive form of neonatal diabetes. Not all genetic mutations causing neonatal diabetes respond to glibenclamide, and starting therapy without proper genetic characterization may delay appropriate treatment. Genetic testing of the KCNJ11, ABCC8, and other relevant genes should be performed as early as possible after diagnosis.
Contraindications
AMGLIDIA must not be used in patients with:
- Hypersensitivity to glibenclamide, other sulfonylureas, sulfonamides, or any of the excipients
- Diabetic ketoacidosis – this is a medical emergency requiring insulin therapy
- Type 1 diabetes mellitus – glibenclamide requires functional beta cells and is not effective in autoimmune diabetes
- Severe hepatic impairment – glibenclamide is extensively metabolized by the liver
- Severe renal impairment – reduced clearance increases the risk of prolonged hypoglycemia
- Acute porphyria – sulfonylureas may precipitate porphyric crises
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency – sulfonylureas may trigger hemolytic anemia
- Concomitant use of bosentan – this combination is contraindicated due to increased risk of liver toxicity
Warnings and Precautions
Several important precautions should be observed when using AMGLIDIA:
Hypoglycemia risk: The most important safety concern with AMGLIDIA is hypoglycemia (low blood sugar). Blood glucose must be monitored carefully during initial dose titration and any subsequent dose adjustments. Parents and caregivers should be educated about the signs of hypoglycemia in neonates and infants, which may include irritability, poor feeding, lethargy, jitteriness, and seizures. Treatment for mild hypoglycemia includes feeding glucose-containing fluids; severe episodes may require intravenous dextrose.
Sodium benzoate content: AMGLIDIA contains sodium benzoate (E211) at 5 mg per mL, which may increase the risk of jaundice in newborns up to 4 weeks of age. In these very young patients, the clinical benefit of treatment must be carefully weighed against this risk. Sodium benzoate may displace bilirubin from albumin binding sites, potentially increasing the risk of kernicterus in neonates with elevated bilirubin levels.
Sodium content: Each mL of AMGLIDIA contains 2.8 mg of sodium. This should be taken into account for patients on a controlled sodium diet, though the amounts involved are typically small given the usual dosing volumes.
Transition from insulin: When transitioning a patient from insulin to AMGLIDIA, the process should be carefully managed in a clinical setting with close glucose monitoring. Insulin doses should be gradually reduced as glibenclamide doses are increased, and there may be a period of overlap where both medications are used concurrently.
Pregnancy and Breastfeeding
The pregnancy and breastfeeding considerations for AMGLIDIA are unique because the primary patient population is neonates and young children. However, some relevant considerations apply:
In cases where a mother with a KCNJ11 mutation is treated with glibenclamide during pregnancy, transplacental transfer of the drug can occur. Studies have documented that maternal glibenclamide use can cause neonatal hyperinsulinemic hypoglycemia in non-affected newborns, as well as fetal macrosomia (large birth weight) and neonatal respiratory distress. Careful neonatal monitoring is essential when the mother has been taking sulfonylureas during pregnancy.
Glibenclamide is excreted in breast milk, though the clinical significance of this in the context of neonatal diabetes treatment is limited since the infant may already be receiving direct treatment with the same medication.
Never adjust the dose of AMGLIDIA without consulting the prescribing physician. Incorrect dosing can lead to dangerous hypoglycemia in neonates and infants. Always use the graduated oral syringe provided with the medication for accurate measurement.
How Does AMGLIDIA Interact with Other Drugs?
AMGLIDIA (glibenclamide) has several clinically significant drug interactions. Bosentan is contraindicated due to liver toxicity risk. Azole antifungals (miconazole, fluconazole) can significantly increase hypoglycemia risk. Corticosteroids and thiazide diuretics may reduce efficacy by raising blood glucose levels.
Drug interactions with glibenclamide can be broadly categorized into those that increase the risk of hypoglycemia (by potentiating the drug's effect) and those that reduce glycemic control (by antagonizing its action). Given that AMGLIDIA is used in neonates and infants, who may be receiving multiple medications in clinical settings, awareness of these interactions is essential for safe prescribing.
Glibenclamide is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9, with additional metabolism by CYP3A4. Drugs that inhibit or induce these enzymes can significantly alter glibenclamide plasma concentrations and clinical effects. The drug is also highly protein-bound (approximately 99%), meaning that displacement interactions with other protein-bound drugs can occur.
Major Interactions
| Interacting Drug | Effect | Clinical Action |
|---|---|---|
| Bosentan | Increased risk of hepatotoxicity; reduced efficacy of both drugs | Contraindicated – do not use together |
| Miconazole (oral/systemic) | Strong CYP2C9 inhibitor; dramatically increases glibenclamide levels | Avoid combination; high risk of severe hypoglycemia |
| Fluconazole | CYP2C9 inhibitor; increases glibenclamide exposure | Monitor glucose closely; dose reduction may be needed |
| ACE inhibitors | May enhance hypoglycemic effect of sulfonylureas | Increase glucose monitoring frequency |
| NSAIDs | Protein displacement; increased free glibenclamide levels | Monitor glucose closely; reduce dose if needed |
Minor Interactions and Efficacy-Reducing Drugs
| Drug Class | Effect on Blood Glucose | Management |
|---|---|---|
| Corticosteroids | Raise blood glucose; may counteract glibenclamide | Monitor glucose; may need dose increase |
| Thiazide diuretics | Impair insulin secretion; reduce glycemic control | Monitor glucose; consider alternative diuretic |
| Beta-blockers | May mask hypoglycemia symptoms; variable effect on glucose | Use with caution; enhance glucose monitoring |
| Colesevelam | Reduces glibenclamide absorption from GI tract | Give AMGLIDIA at least 4 hours before colesevelam |
| Rifampicin | CYP inducer; reduces glibenclamide plasma levels | Monitor glucose; significant dose increase may be needed |
What Is the Correct Dosage of AMGLIDIA?
AMGLIDIA dosing is highly individualized based on genetic mutation type and clinical response. The typical starting dose is 0.2 mg/kg/day in two divided doses, with gradual increases up to a maximum of 2.8 mg/kg/day. Two strengths are available (0.6 mg/mL and 6 mg/mL) to enable precise titration across all age groups.
Dosing of AMGLIDIA must be individualized for each patient. The optimal dose depends on the type of genetic mutation, the patient's age and weight, and their individual response to therapy. The prescribing physician will determine the starting dose and titration schedule based on these factors. Blood glucose levels should be monitored closely during the initial dose titration period and whenever doses are adjusted.
Neonates and Infants
Starting Dose
The recommended starting dose is 0.2 mg/kg/day, divided into two doses administered before feeds. An alternative approach is to start with 0.05 mg/kg per dose given every 4 hours before feeding (approximately 0.3 mg/kg/day total).
Dose Titration
If blood glucose control is not achieved, the dose may be gradually increased. Most patients achieve adequate glycemic control at 0.2 to 0.5 mg/kg/day. Some patients with certain mutations may require higher doses, up to a maximum of 2.8 mg/kg/day, which has been used safely in clinical studies without significant adverse effects.
Older Children
Maintenance Therapy
Children who have been successfully transitioned from insulin to AMGLIDIA typically continue on a stable maintenance dose. The 6 mg/mL strength is more convenient for older children who require higher volumes. Dose adjustments may be needed during periods of rapid growth, illness, or changes in diet and activity levels.
| Parameter | Recommendation | Notes |
|---|---|---|
| Starting dose | 0.2 mg/kg/day in 2 doses | Given before feeds |
| Alternative start | 0.05 mg/kg every 4 hours | Before each feeding |
| Typical maintenance | 0.2–0.5 mg/kg/day | Divided into 2 doses |
| Maximum dose | 2.8 mg/kg/day | For partial responders |
| HbA1c monitoring | Every 3 months | In all patients |
Missed Dose
If a dose of AMGLIDIA is missed, it should be given as soon as remembered, provided the next scheduled dose is not imminent. If it is close to the time for the next dose, the missed dose should be skipped. Never give a double dose to make up for a missed one, as this significantly increases the risk of hypoglycemia. Contact the prescribing physician if multiple doses have been missed or if blood glucose levels are difficult to manage.
Overdose
An overdose of AMGLIDIA can cause severe, prolonged hypoglycemia, which is a medical emergency. Symptoms of overdose in neonates and infants include severe lethargy, poor feeding, seizures, and loss of consciousness. Immediate treatment requires intravenous glucose (dextrose) administration, and the patient should be monitored in a hospital setting for at least 24-48 hours, as glibenclamide has a long duration of action and hypoglycemia may recur after initial correction.
If you suspect an overdose of AMGLIDIA, seek emergency medical attention immediately. Hypoglycemia from glibenclamide overdose can be prolonged and life-threatening, especially in neonates. Do not wait for symptoms to develop – contact emergency services or your local poison control center right away.
What Are the Side Effects of AMGLIDIA?
The most common side effect of AMGLIDIA is hypoglycemia (low blood sugar), which is typically mild to moderate when doses are carefully titrated. Other side effects include transient diarrhea, nausea, and abdominal discomfort. Serious but rare side effects include severe hypoglycemia, angioedema, and neutropenia.
Like all medications, AMGLIDIA can cause side effects, although not everyone experiences them. The side effect profile of glibenclamide in the neonatal diabetes population differs somewhat from its use in type 2 diabetes in adults, partly because of the different underlying pathophysiology and the unique pharmacokinetics in neonates and infants.
Clinical studies, including the pivotal NEOGLI trial and extensive post-marketing experience, have established the following safety profile for AMGLIDIA in the neonatal diabetes population. The frequency categories follow the standard classification used by the EMA.
Very Common (affects more than 1 in 10 patients)
- Hypoglycemia (low blood sugar) – the most frequently reported adverse effect, particularly during initial dose titration
- Transient diarrhea – usually mild and self-resolving within the first weeks of treatment
Common (affects 1 to 10 in 100 patients)
- Nausea and vomiting
- Abdominal pain or discomfort
- Dyspepsia (heartburn)
- Decreased appetite
Uncommon (affects 1 to 10 in 1,000 patients)
- Skin rash or urticaria
- Transitory elevated liver enzymes (transaminases)
- Neutropenia (low white blood cell count)
- Blurred vision
Rare (affects fewer than 1 in 1,000 patients)
- Angioedema (severe allergic swelling)
- Severe hypoglycemia with seizures or loss of consciousness
- Cholestatic jaundice
- Blood dyscrasias (thrombocytopenia, agranulocytosis)
In the neonatal diabetes population specifically, clinical experience has shown that hypoglycemia episodes are typically mild to moderate in severity. A comprehensive review of published case series found that no cases of severe hypoglycemia involving unconsciousness or seizures were reported when glibenclamide was initiated and titrated under appropriate medical supervision. The risk of hypoglycemia is highest during the initial dose titration period and decreases as a stable maintenance dose is established.
Parents and caregivers should be trained to recognize the signs of hypoglycemia in neonates and infants, which may differ from older children and adults. Key signs to watch for include unusual irritability or crying, poor feeding or refusal to eat, excessive sleepiness or lethargy, jitteriness or trembling, pallor, and in severe cases, seizures. Blood glucose should be checked promptly if any of these signs are observed.
Contact your healthcare provider if your child experiences recurrent episodes of low blood sugar, persistent gastrointestinal symptoms (diarrhea, vomiting), any signs of an allergic reaction (rash, swelling), or if you notice unusual bruising or bleeding. Seek emergency medical care immediately for seizures, loss of consciousness, or severe allergic reactions.
How Should You Store AMGLIDIA?
Store AMGLIDIA in its outer carton to protect from light. Keep the bottle tightly closed. Unopened bottles have a shelf life of 3 years. Once opened, use within 30 days. Do not freeze. Store at room temperature.
Proper storage of AMGLIDIA is essential to maintain the medication's stability and effectiveness. As an oral suspension, AMGLIDIA requires specific storage conditions to ensure that the active ingredient remains uniformly distributed and that the formulation retains its pharmacological activity throughout its shelf life.
AMGLIDIA is supplied in a brown glass bottle (Type III) with a child-resistant polypropylene screw cap. The brown glass provides additional protection from light degradation. Each carton also includes a graduated oral syringe (either 1 mL or 5 mL, depending on the strength) and a bottle adaptor for accurate dose measurement.
- Temperature: Store at room temperature. Do not freeze or refrigerate
- Light protection: Keep the bottle in its outer carton at all times to protect from light
- Container: Keep the bottle tightly closed when not in use
- Shelf life (unopened): 3 years from date of manufacture
- Shelf life (after opening): 30 days – discard any remaining suspension after this period
- Before use: Shake the bottle gently before each dose to ensure uniform suspension
- Syringe care: Rinse the oral syringe with clean water after each use
- Child safety: Store out of reach and sight of children, despite the child-resistant closure
Write the date of opening on the bottle label to keep track of the 30-day use period. Do not use AMGLIDIA after the expiry date printed on the carton and bottle label. Expired medication should be returned to a pharmacy for proper disposal. Do not dispose of medications via household waste or wastewater.
What Does AMGLIDIA Contain?
AMGLIDIA contains glibenclamide as the active ingredient, available in 0.6 mg/mL and 6 mg/mL strengths. Excipients include hydroxyethylcellulose, xanthan gum, lactic acid, sodium citrate, sodium benzoate (preservative), and purified water. It appears as a white oral suspension.
Understanding the full composition of AMGLIDIA is important for identifying potential sensitivities or allergies to any of the ingredients, and for healthcare providers making prescribing decisions in patients with specific dietary or medical requirements.
Active Ingredient
Glibenclamide (also known internationally as glyburide) is a second-generation sulfonylurea antidiabetic agent. Each milliliter of AMGLIDIA contains either 0.6 mg or 6 mg of glibenclamide, depending on the strength prescribed. The lower strength (0.6 mg/mL) is typically used for neonates and very young infants requiring small doses, while the higher strength (6 mg/mL) is more suitable for older children who need larger doses.
Excipients
| Excipient | Function | Notable Information |
|---|---|---|
| Hydroxyethylcellulose | Suspending agent; maintains uniform distribution | Non-toxic, widely used in pharmaceutical suspensions |
| Xanthan gum | Thickener and stabilizer | Natural polysaccharide; well tolerated |
| Lactic acid | pH adjustment | Maintains optimal pH for drug stability |
| Sodium citrate | Buffer system | Contributes to sodium content |
| Sodium benzoate (E211) | Preservative (antimicrobial) | 5 mg/mL; may increase jaundice risk in neonates <4 weeks |
| Purified water | Vehicle/solvent | Pharmaceutical grade |
The sodium content of AMGLIDIA is 2.8 mg per mL. For the 0.6 mg/mL strength, the sodium content per dose is typically small. However, healthcare providers should take this into account when prescribing to patients on sodium-restricted diets or those receiving other sodium-containing medications concurrently.
AMGLIDIA does not contain any sugar, gluten, lactose, or artificial colors. This makes it suitable for patients with common food intolerances. The suspension has a neutral taste, which aids acceptability in neonates and infants.
Frequently Asked Questions About AMGLIDIA
AMGLIDIA is an oral suspension of glibenclamide specifically developed for treating neonatal diabetes mellitus (NDM) in newborns, infants, and children. It is particularly effective in patients with mutations in the KCNJ11 or ABCC8 genes, which cause dysfunction of the KATP channels in pancreatic beta cells. In many of these patients, AMGLIDIA can replace daily insulin injections with a simpler oral medication, significantly improving quality of life. It was approved by the EMA in 2018 with orphan drug status due to the extreme rarity of the condition.
AMGLIDIA is the first and only commercially available oral suspension of glibenclamide. Unlike standard tablets, it provides consistent drug concentration in a liquid form that can be precisely measured using the graduated oral syringe provided. This is critically important for neonates and infants who cannot swallow tablets and require very small, precise doses. Before AMGLIDIA, healthcare providers had to prepare extemporaneous (compounded) liquid formulations from crushed tablets, which led to inconsistent dosing and variable bioavailability.
Yes, in many cases of neonatal diabetes caused by KATP channel mutations (KCNJ11 or ABCC8 genes), patients can successfully transition from insulin injections to oral AMGLIDIA. Clinical studies have demonstrated that glibenclamide provides equal or superior glycemic control compared to continuous subcutaneous insulin infusion in these patients. However, not all genetic forms of neonatal diabetes respond to sulfonylureas, which is why genetic testing is essential before attempting the switch. The transition should always be done under close medical supervision with careful blood glucose monitoring.
If a dose is missed, give it as soon as you remember, provided the next scheduled dose is not too close. If it is nearly time for the next dose, skip the missed dose and continue with the regular schedule. Never give a double dose to compensate, as this can cause dangerous hypoglycemia. If you are unsure about what to do, or if several doses have been missed, contact your child's healthcare provider for guidance. Monitor blood glucose levels more frequently following a missed dose.
Once opened, AMGLIDIA must be used within 30 days. Write the date of opening on the bottle label to keep track. After 30 days, any remaining suspension should be discarded, even if the bottle is not empty. Unopened bottles have a shelf life of 3 years from the date of manufacture. Always store AMGLIDIA in its outer carton to protect from light, and keep the bottle tightly closed. Do not freeze the suspension.
Signs of hypoglycemia (low blood sugar) in neonates and infants can be subtle and may differ from those seen in older children and adults. Watch for: unusual irritability or inconsolable crying, poor feeding or refusal to eat, excessive sleepiness or lethargy, jitteriness or trembling, pale or bluish skin color, sweating, and in severe cases, seizures or loss of consciousness. If you suspect hypoglycemia, check blood glucose immediately and offer a glucose-containing feed. For severe symptoms (seizures, unresponsiveness), seek emergency medical attention immediately.
References
- European Medicines Agency (EMA). AMGLIDIA (glibenclamide) – EPAR Summary for the Public. EMA/491856/2018. Available at: ema.europa.eu/en/medicines/human/EPAR/amglidia
- Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467-477. doi:10.1056/NEJMoa061759
- Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355(5):456-466. doi:10.1056/NEJMoa055068
- Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31(2):204-209. doi:10.2337/dc07-1785
- De Franco E, Flanagan SE, Houghton JAL, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes. Lancet. 2015;386(9997):957-963. doi:10.1016/S0140-6736(15)60098-8
- World Health Organization (WHO). WHO Model List of Essential Medicines for Children – 8th List. Geneva: WHO; 2021.
- Shepherd MH, Shields BM, Hammersley S, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the UK pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39(11):1879-1888. doi:10.2337/dc16-0645
- Lemelman MB, Letourneau L, Bhatt DL, et al. Neonatal diabetes mellitus: An update on diagnosis and management. Clin Perinatol. 2018;45(1):41-59. doi:10.1016/j.clp.2017.10.006
- British National Formulary for Children (BNFc). Glibenclamide. National Institute for Health and Care Excellence (NICE). Updated 2024.
- International Society for Pediatric and Adolescent Diabetes (ISPAD). ISPAD Clinical Practice Consensus Guidelines 2022: Monogenic diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1188-1211.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians in pediatric endocrinology, neonatology, and clinical pharmacology. Our editorial process follows evidence-based medicine principles with systematic review of current literature and international clinical guidelines.
Content developed by physicians with clinical experience in pediatric diabetes and rare metabolic disorders, following EMA, WHO, and ISPAD guidelines.
Independently reviewed by the iMedic Medical Review Board. All clinical claims verified against peer-reviewed literature and regulatory documentation.
Evidence Level 1A based on systematic reviews, randomized controlled trials, and regulatory agency assessments (EMA EPAR). GRADE framework applied.
No pharmaceutical company funding or sponsorship. Independent medical editorial content with no conflicts of interest.